Elsevier

NeuroToxicology

Volume 26, Issue 3, June 2005, Pages 361-371
NeuroToxicology

Effects of Homocysteine on the Dopaminergic System and Behavior in Rodents

https://doi.org/10.1016/j.neuro.2005.01.008Get rights and content

Abstract

Long-term treatment of levodopa for Parkinson's disease (PD) patients is known to elevate homocysteine level in their plasma. The present study was designed to examine the possible neurotoxic effects of the increased homocysteine level on the dopaminergic system. Homocysteine was administered into Sprague–Dawley male rats intracerebroventricularly or C57BL/6 mice intraperitoneally. Following homocysteine injection the locomotor activities, the levels of dopamine (DA) and its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and immunohistochemistry of dopaminergic neurons were examined. The results obtained indicate that homocysteine administration (1 or 2 μmol, i.c.v.) into the rat brains for 5 days significantly decreased the locomotor activities and dopamine as well as its metabolites, DOPAC and HVA, in the rat striatal regions. Two different doses of homocysteine (50 and 100 mg/100 g, i.p. daily) were administered into mice for 36 days to evaluate the effect of systemic treatment of homocysteine on the dopaminergic neurons of the brain. The intraperitoneal injections of two doses of homocysteine significantly increased homocysteine levels in the striatal regions of mouse brains by 21.5 and 39.2%, while reducing dopamine turnover rates in the striatal regions by decreasing (DOPAC + HVA)/DA, 23.7 and 51.6%, respectively. Accordingly, homocysteine decreased locomotor activities significantly by decreasing movement time by 29 and 38%, total distance by 32 and 42%, and numbers of movement by 28 and 41%, respectively. Moreover, homocysteine decreased tyrosine hydroxylase immunoreactivity in substantia nigra of mouse brain. The data obtained indicate that the potential of homocysteine to be toxic to the dopaminergic system. Consequently, long-term levodopa therapy for PD may accelerate the progression of PD, at least in part by elevated homocysteine.

Section snippets

INTRODUCTION

Parkinson's disease (PD) is a progressive neurological disorder resulted from dopaminergic cell death and dopamine depletion (Hornykiewicz, 1966). Since the etiology of PD remains to be elucidated, the strategy of current treatments of PD patients is symptomatic with efforts to slowdown the progression of the disease. l-3,4-Dihydroxyphenylalanine (levodopa) is a precursor of dopamine and represents the most effective medication for PD treatment.

When levodopa serves as a precursor of dopamine,

Animals

Male Sprague–Dawley rats weighing 180–200 g and male C57BL/6 mice 4 weeks old were purchased from Harlan (Indianapolis, IN). Animals were kept in the animal care facility until the beginning of experiments and had access to food and water ad libitum, under a 12 h light/dark cycle. Temperature was maintained at 21 ± 1 °C.

Chemicals

Homocysteine, 3-O-methyldopa, adenosine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), tri-n

Effects of Homocysteine, Adenosine, and 3-OMD on Dopamine Turnover in Rat Brain Striatum

SAM-dependent methylation of levodopa results in the production of 3-OMD as well as S-adenosylhomocysteine (SAH) which is readily hydrolyzed by SAH hydrolase to adenosine and homocysteine (Fig. 1). The present study was focused on homocysteine effects to determine the possible role of elevated homocysteine in pathological conditions such as PD with levodopa treatment. Three possible metabolites of levodopa, homocysteine, 3-OMD and adenosine, were also tested.

Sprague–Dawley male rats were

DISCUSSION

The findings of our study reveal that homocysteine significantly decreased locomotor activities in rats and mice. Homocysteine also caused severe reduction of dopamine turnover in the striatum and decreased TH immunoreactivity in substantia nigra of mouse brain after chronic exposure, implicating that elevated homocysteine could cause harmful impacts on the dopaminergic nervous system. These results indicate that elevated homocysteine could be associated with the complications of levodopa

ACKNOWLEDGEMENTS

This work was supported by grants received from the National Institutes of Health (RO1 28432, RR 03020, and GM 08111).

REFERENCES (49)

  • M.P. Mattson et al.

    Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders

    Trends Neurosci

    (2003)
  • A.L. McCormack et al.

    Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat

    Neurobiol Dis

    (2002)
  • B. Meldrum

    Amino acids as dietary excitotoxins: a contribution to understanding neurodegenerative disorders

    Brain Res Brain Res Rev

    (1993)
  • T. Muller et al.

    Nigral endothelial dysfunction, homocysteine, and Parkinson's disease

    Lancet

    (1999)
  • T. Muller et al.

    Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease

    Neurosci Lett

    (2001)
  • I.J. Perry et al.

    Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men

    Lancet

    (1995)
  • N.S. Sharpless et al.

    Dopa and 3-O-methyldopa in cerebrospinal fluid of Parkinsonism patients during treatment with oral l-dopa

    Clin Chim Acta

    (1971)
  • R.T. Wall et al.

    Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury

    Thromb Res

    (1980)
  • W.Q. Zhao et al.

    l-Dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase

    Exp Neurol

    (2001)
  • P. Allain et al.

    Sulfate and cysteine levels in the plasma of patients with Parkinson's disease

    Neurotoxicology

    (1995)
  • F. Andreotti et al.

    Homocysteine and risk of cardiovascular disease

    J Thromb Thrombolysis

    (2000)
  • G. Bartholini et al.

    Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase

    J Pharmacol Exp Ther

    (1968)
  • R. Benson et al.

    The effects of l-dopa on the activity of methionine adenosyltransferase: relevance to l-dopa therapy and tolerance

    Neurochem Res

    (1993)
  • M.L. Bots et al.

    Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam study

    Arch Intern Med

    (1999)
  • Cited by (91)

    • Polyneuropathy in levodopa-treated Parkinson's patients

      2016, Journal of the Neurological Sciences
    • Oxidative stress and mitochondrial dysfunction are the underlying events of dopaminergic neurodegeneration in homocysteine rat model of Parkinson's disease

      2016, Neurochemistry International
      Citation Excerpt :

      Our results that unilateral intranigral infusion of Hcy causes motor abnormalities, reduction of striatal dopamine level and degeneration of midbrain dopaminergic neurons (Fig. 2), which are similar to that in PD, are consistent with the earlier report (Chandra et al., 2006). Elevated Hcy levels in PD patients with or without l-DOPA therapy (Kuhn et al., 1998; Louis et al., 2007; Zoccolella et al., 2010; Hu et al., 2013) is of great concern as several independent studies have reported Hcy as a putative neurotoxin to dopaminergic neurons (Chandra et al., 2006; Duan et al., 2002; Lee et al., 2005). Intranigral or intrastriatal injection of Hcy was reported to exacerbate dopamine loss, dopaminergic neuronal loss and motor dysfunction in rodent model of PD; however Hcy alone failed to show any significant effect (Duan et al., 2002).

    • L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room

      2016, Biochimica et Biophysica Acta - General Subjects
    View all citing articles on Scopus
    View full text